Drug intelligence / Profile preview

nChroma Bio CNS epigenetic editor program

Development stage: Preclinical
Lead developer: nChroma Bio
Modality: Gene Therapies, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules

Overview

nChroma Bio's CNS program focuses on the development of smaller, next-generation epigenetic editors specifically optimized for in vivo delivery to the central nervous system (CNS). These editors are designed to precisely modulate the expression of disease-relevant genes by modifying epigenetic marks—such as DNA methylation—without altering the underlying DNA sequence. This approach aims to provide a durable and potentially safer alternative to traditional gene editing for treating various CNS diseases. The program is currently in the research phase, leveraging nChroma Bio's platform for precise and tunable gene regulation.

Other names: Various CNS Targets

Beyond the preview

Go deeper on nChroma Bio CNS epigenetic editor program.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nChroma Bio CNS epigenetic editor program.